ArticleFrontiers in cardiovascular medicine2026
Association of the inflammatory burden index with 1-year major adverse cardiovascular events in patients with HFpEF after myocardial infarction: a single-center retrospective cohort study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory activation may contribute to adverse remodeling and recurrent cardiovascular events after myocardial infarction (MI), but its prognostic value in patients with heart failure with preserved ejection fraction (HFpEF) remains uncertain. This study evaluated whether the Inflammatory Burden Index (IBI) was associated with 1-year major adverse cardiovascular events (MACE) in patients with HFpEF and documented MI. Method: In this single-centre retrospective cohort study, 625 patients hospitalized at Fuyang People's Hospital from January 2018 to December 2023 were screened. After 33 patients with incomplete follow-up or unavailable baseline data were excluded, 592 patients were included. IBI was calculated as C-reactive protein multiplied by the neutrophil-to-lymphocyte ratio. The Youden-derived IBI cutoff of 7.70 was used only for descriptive grouping and sensitivity analysis. The primary Cox model treated log-transformed IBI (logIBI) as a continuous predictor and adjusted for age, sex, hypertension, diabetes mellitus, LDL-C and soluble ST2. Discrimination, calibration and clinical usefulness were assessed using the C-index, 365-day AUC, Brier score, calibration slope, Hosmer-Lemeshow test and decision curve analysis. Results: During 1-year follow-up, 74 patients experienced MACE (12.5%). Higher logIBI was independently associated with 1-year MACE (HR 1.828, 95% CI 1.529-2.186, Conclusion: In patients with HFpEF and documented MI, higher logIBI was independently associated with 1-year MACE and improved risk discrimination when added to a base clinical model. IBI may provide a practical admission-level measure of residual inflammatory burden, but external validation and prospective assessment are needed before clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.